Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• Synthetic lethality, particularly targeting Poly-ADP-ribose-polymerase (PARP) inhibitors, is a successful strategy for treating homologous recombination (HR)-defective tumors.
• Developing novel therapeutic agents that enhance existing treatment modalities is crucial for improving patient outcomes.

Purpose of the Study:

• To design and synthesize novel hybrid drug conjugates (M1-M3) combining a PARP inhibitor (Olaparib) with a RAD51 inhibitor (Cpd 1).
• To evaluate the anti-survival effects of these hybrid compounds in various breast cancer cell lines and assess their potential for targeted cancer therapy.

Main Methods:

• Synthesis of three hybrid compounds (M1-M3) with varying linker strategies, combining Olaparib and Cpd 1.
• Assessment of anti-survival effects of M1-M3 and parental drugs across six distinct breast cancer cell lines.
• Analysis of differential responses based on breast cancer subtypes (TNBC vs. non-TNBC) and HR status.

Main Results:

• At least one hybrid conjugate (M1-M3) significantly decreased cell viability (one to two orders of magnitude) compared to parental drugs in all tested cell lines.
• Triple-negative breast cancer (TNBC) cells were sensitive to spacer-linked hybrids (M1, M2), irrespective of HR capacity.
• Non-TNBC cells responded specifically to the directly merged conjugate (M1), indicating subtype-specific efficacy.

Conclusions:

• Hybrid drug conjugates targeting both PARP and RAD51 demonstrate potent anti-cancer activity.
• The chemical linkage strategy influences the efficacy and selectivity of these dual-inhibitory drugs across different breast cancer subtypes.
• These findings suggest a potential for developing tailored therapies based on the specific molecular characteristics of breast cancer.